A new trading day began on Tuesday, with Prelude Therapeutics Inc (NASDAQ: PRLD) stock price up 16.44% from the previous day of trading, before settling in for the closing price of $1.46. PRLD’s price has ranged from $0.61 to $4.22 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -21.61%. Meanwhile, its annual earnings per share averaged 20.44%. With a float of $29.84 million, this company’s outstanding shares have now reached $43.75 million.
Prelude Therapeutics Inc (PRLD) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Prelude Therapeutics Inc is 60.59%, while institutional ownership is 21.51%. The most recent insider transaction that took place on Mar 25 ’25, was worth 69,250. In this transaction Chief Chemistry Officer of this company bought 100,000 shares at a rate of $0.69, taking the stock ownership to the 480,123 shares. Before that another transaction happened on Mar 25 ’25, when Company’s CEO bought 675,000 for $0.69, making the entire transaction worth $467,438. This insider now owns 1,999,296 shares in total.
Prelude Therapeutics Inc (PRLD) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.37 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.44% per share during the next fiscal year.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Here are Prelude Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Compared to the last year’s volume of 0.51 million, its volume of 0.34 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 60.49%.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 27.38%, which indicates a significant decrease from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1680 in the past 14 days, which was lower than the 0.1804 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5339, while its 200-day Moving Average is $1.0563. Nevertheless, the first resistance level for the watch stands at $1.7800 in the near term. At $1.8600, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.0200. If the price goes on to break the first support level at $1.5400, it is likely to go to the next support level at $1.3800. Now, if the price goes above the second support level, the third support stands at $1.3000.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
With a market capitalization of 128.71 million, the company has a total of 62,865K Shares Outstanding. Currently, annual sales are 7,000 K while annual income is -127,170 K. The company’s previous quarter sales were 6,500 K while its latest quarter income was -19,730 K.
